Grand Challenges in Pediatric Endocrinology by Cianfarani, Stefano
www.frontiersin.org  September 2010  | Volume 1  | Article 1  |  1
Specialty Grand challenGe article
published: 30 September 2010
doi: 10.3389/fendo.2010.00001
Grand challenges in pediatric endocrinology
Stefano Cianfarani*
Molecular Endocrinology Unit, D.P .U.O. ‘Bambino Gesù’ Children’s Hospital and ‘Rina Balducci’ Center of Pediatric Endocrinology, Tor Vergata University, Rome, Italy
*Correspondance: stefano.cianfarani@uniroma2.it
Pediatric Endocrinology strives to advance 
the  understanding  and  management  of 
endocrine diseases in childhood. Although 
both basic and clinical research have pro-
vided important new insights into many 
endocrine diseases, the mechanisms under-
lying several clinical conditions have not 
yet been elucidated and many new poten-
tial  therapeutic  interventions  remain  to 
be tested. It has also become increasingly 
apparent that experiences and exposures 
throughout  fetal  life  and  childhood  can 
have important effects on many diseases 
that develop much later during adult life. 
Alterations to the endocrine system medi-
ate many of these long-term effects and 
understanding  how  these  changes  occur 
and how they translate into compromised 
health  in  adulthood  have  become  addi-
tional  questions  that  confront  pediatric 
endocrinologists.
I will quote only a few examples of the 
grand challenges that wait to be tackled in 
the near future.
There  is  increasing  evidence  that  the 
hypothalamus is involved in the regulation 
of energy balance and glucose homeostasis 
and, ultimately, in the occurrence of dia-
betes (Elmquist and Marcus, 2003; Prodi 
and  Obici,  2006).  In  humans,  however, 
studies on the brain control of metabolism 
and endocrine system are difficult and only 
translational research will provide robust 
data to be translated into clinical practice. 
Although the transfer of information from 
basic to clinical science requires hard work 
and is often disappointing, it is certainly 
worthwhile as shown by the results achieved 
in other disciplines such as Oncology.
For almost a century endocrine research 
has focused on the interaction between hor-
mones and their receptors, providing major 
advances  in  the  understanding  of  endo-
crine system physiology. More recently, the 
research focus has shifted to the pathways 
downstream from the receptor. The study of 
intracellular hormone signaling has revealed 
that some endocrine diseases may originate 
from  alterations  of  signal    transduction 
(Kofoed et al., 2003). It is easy to foresee 
that further investigations will reveal that 
many yet unexplained endocrinopathies are 
the result of subtle alterations of intracel-
lular signaling.
Novel genes have recently been discov-
ered to play a pivotal role in the regulation 
of reproduction and growth (Weedon and 
Frayling, 2008; Bianco and Kaiser, 2009). 
Genome  wide  association  analysis  has 
revealed the influence of many unexpected 
genes in the control of growth, puberty and 
diabetes (Dateki et al., 2008; Zeggini et al., 
2008; Ong et al., 2009). This new large-scale 
genetic approach challenges the research-
ers to obtain more complete descriptions 
of the susceptibility architecture of endo-
crine traits and to translate the informa-
tion gathered into improvements in clinical 
management.  However,  the  mechanisms 
by which genetic information is translated 
into phenotypic features and diseases as 
well  as  those  underlying  the  interaction 
among hundreds of genes are still largely 
unknown. Genetic manipulation of experi-
mental species, which uses transgenic and 
gene-knockout technology, has led and will 
lead to important advances in determin-
ing the relationship between genes and the 
function of their encoded proteins in the 
intact organism.
Alterations  in  the  embryo-fetal  and 
early  postnatal  hormonal  environment, 
caused by either maternal diet or exposure 
to environmental factors, can modify the 
epigenome,  and  these  modifications  are 
inherited  in  somatic  daughter  cells  and 
maintained  throughout  life,  ultimately 
leading to permanent metabolic and endo-
crine changes (Gluckman et al., 2008). We 
are at the beginning of the epigenomics era 
that may provide important insights to be 
translated into interventions to revert epi-
genetic programming. Early prevention of 
adult diseases is nowadays a primary objec-
tive of Pediatrics in general and Pediatric 
Endocrinology in particular. Obesity, dia-
betes,  hypertension  and  cardiovascular 
disease in adulthood may originate during 
  embryo-fetal   development and early post-
natal  life  (Barker  et  al.,  1989;  Robinson 
et al., 1992; Barker, 1995). Therefore, the 
elucidation of environmental, (epi)genetic, 
and endocrine mechanisms leading to long-
term metabolic risk represents a primary 
task of the Pediatric Endocrinologist.
The  last  two  decades  have  witnessed 
growing concerns over the potential adverse 
effects that may result from exposure to a 
group of chemicals that have the poten-
tial to alter the normal functioning of the 
endocrine system in wildlife and humans. 
Potential adverse outcomes in both wild-
life and humans have focused mainly on 
reproductive and sexual development and 
function, altered immune and nervous sys-
tem, thyroid function and hormone-related 
cancers. Analysis of the human data by itself, 
while generating concerns, has so far failed 
to provide firm evidence of direct causal 
associations between exposure to endocrine 
disruptors  and  adverse  health  outcomes. 
Our current understanding of the effects 
posed by endocrine disruptors to humans 
is incomplete. Uncertainty over the possible 
effects of chronic exposures to a number of 
chemicals with endocrine disrupting poten-
tial and the fundamental role played by the 
endocrine system in maintaining homeos-
tasis make the study of the effects posed by 
exposure to these chemicals a worldwide 
research priority.
Further challenges come from the devel-
opment of novel therapeutic approaches 
to endocrine diseases in childhood. New 
drug  formulations,  individualized  treat-
ments  based  on  pharmacogenomics,  as 
well as gene and stem cell therapies repre-
sent further research fields for the Pediatric 
Endocrinologist of the 21st century.
Despite the decline in the total number 
of young pediatricians who are choosing 
subspecialties,  the  demands  for  pediat-
ric  research  expertise  in  all  disciplines, 
especially  endocrinology,  are  increas-
ing. American and European Regulatory 
Agencies (Food and Drug Administration, 
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EMA)  now  require  studies  specifically 
designed  to  investigate  pharmacologi-
cal and toxicological aspects in pediatric 
populations, to test efficacy and safety and 
to  identify  the  appropriate  dosages  and 
formulations.  This  will  therefore  be  an 
increasing  demand  that  will  require  the 
expertise of pediatric subspecialists.
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